Clinical trial
A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents With Growth Failure or Short Stature Due to Growth Hormone Sufficient Disorders - Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature
NCT07221851 is registered in ClinicalTrials.gov with Ascendis Pharma A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents With Growth Failure or Short Stature Due to Growth Hormone Sufficient Disorders - Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature
- Lead sponsor
- Ascendis Pharma A/S
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 12, 2025
- Completion date
- March 31, 2029
- Enrollment
- 186 (estimated)
- Sites
- 51
Conditions
As the registry lists them; a condition with its own page is linked.
idiopathic short stature, short stature homeobox gene mutation, small for gestational age at delivery, turner syndrome